Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
ALEC-04 by Alentis Therapeutics for Nasopharyngeal Cancer: Likelihood of Approval
ALEC-04 is under clinical development by Alentis Therapeutics and currently in Phase II for Nasopharyngeal Cancer. According to GlobalData, Phase...
ALEC-04 by Alentis Therapeutics for Oral Cavity (Mouth) Cancer: Likelihood of Approval
ALEC-04 is under clinical development by Alentis Therapeutics and currently in Phase II for Oral Cavity (Mouth) Cancer. According to...
ALEC-04 by Alentis Therapeutics for Hypopharyngeal Cancer: Likelihood of Approval
ALEC-04 is under clinical development by Alentis Therapeutics and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData, Phase...
Lixudebart by Alentis Therapeutics for Idiopathic Pulmonary Fibrosis: Likelihood of Approval
Lixudebart is under clinical development by Alentis Therapeutics and currently in Phase I for Idiopathic Pulmonary Fibrosis. According to GlobalData,...
Lixudebart by Alentis Therapeutics for Liver Fibrosis: Likelihood of Approval
Lixudebart is under clinical development by Alentis Therapeutics and currently in Phase I for Liver Fibrosis. According to GlobalData, Phase...
Lixudebart by Alentis Therapeutics for Kidney Fibrosis: Likelihood of Approval
Lixudebart is under clinical development by Alentis Therapeutics and currently in Phase II for Kidney Fibrosis. According to GlobalData, Phase...
Lixudebart by Alentis Therapeutics for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis): Likelihood of Approval
Lixudebart is under clinical development by Alentis Therapeutics and currently in Phase II for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis)....